Catheter Precision (VTAK) announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 LockeT sales are already outpacing Q2 2024 sales with a 200% increase. Catheter Precision now has several US hospitals that are on track to issue more than $100,000 in purchase orders each for LockeT by the end of 2025. These hospitals include Montefiore, Eisenhower Health, and Overland Park Regional Medical Center.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision Stock (VTAK) Rockets 170% on a Delayed Investor Reaction
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
- Catheter Precision secures VIVO purchase order
- Catheter Precision Approves Warrant Issuance to Ladenburg
- Catheter Precision Announces CCO Departure and Leadership Change